XML 63 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Income (Loss) Per Share (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Numerator        
Net income (loss) attributable to Inovio Pharmaceuticals, Inc. $ (20,759,338) $ 5,594,468 $ (47,506,869) $ (11,235,561)
Reflect adjustment for decrease in fair value of warrant liability (2,841) (616,477) 0 (928,978)
Numerator for use in diluted income (loss) per share $ (20,762,179) $ 4,977,991 $ (47,506,869) $ (12,164,539)
Denominator        
Weighted average number of common shares outstanding (shares) 73,602,834 72,029,644 72,932,199 66,846,481
Effect of dilutive potential common shares from warrants (shares) 186,174 1,931,593 0 172,480
Denominator for use in diluted income (loss) per share (shares) 73,789,008 73,961,237 72,932,199 67,018,961
Net income (loss) per share, diluted ($ per share) $ (0.28) $ 0.07 $ (0.65) $ (0.18)
Antidilutive securities excluded from computation of earnings per share, amount (shares) 7,527,752 2,820,641 7,811,843 6,694,571
Options to purchase commons stock [Member]        
Denominator        
Antidilutive securities excluded from computation of earnings per share, amount (shares) 6,747,961 2,812,185 6,747,961 5,875,211
Warrants to purchase common stock [Member]        
Denominator        
Antidilutive securities excluded from computation of earnings per share, amount (shares)     284,091 580,904
Restricted stock units [Member]        
Denominator        
Antidilutive securities excluded from computation of earnings per share, amount (shares) 771,335 0 771,335 230,000
Convertible preferred stock [Member]        
Denominator        
Antidilutive securities excluded from computation of earnings per share, amount (shares) 8,456 8,456 8,456 8,456